ABSTRACT
Introduction
Knee osteoarthritis (OA) is a joint disease, affecting multiple tissues in the joint. Early detection and intervention may delay OA development and avoid total knee arthroplasty. Specific biomarker profiles for early detection and guiding clinical decision-making of OA have not yet been identified. One technique that can contribute to the finding of this ‘OA biomarker’ is mass spectrometry (MS), which offers the possibility to analyze different molecules in tissues or fluids. Several proteomic, lipidomic, metabolomic and other – omic approaches aim to identify these molecular profiles; however, variation in methods and techniques complicate the finding of promising candidate biomarkers.
Areas covered
In this systematic review, we aim to provide an overview of molecules in knee OA patients. Possible biomarkers in several tissue types of OA and non-OA patients, as well as current limitations and possible future suggestions will be discussed.
Expert opinion
According to this review, we do not believe one specific biomarker will function as predictive molecule for OA. Likely, a group of molecules will give insight in OA development and possible therapeutic targets. For clinical implementation of MS-analysis in clinical decision-making, standardized procedures, large cohort studies and sharing protocols and data is necessary.
Supplemental Material
Supplemental data for this article can be accessed here
Article highlights
Mass spectrometry (imaging) is a promising tool for the detection (and can provide spatial information) of biomarkers for osteoarthritis.
In the literature, synovial fluid is found to be the preferred source in the search for biomarkers for osteoarthritis when analyzing proteins, lipids or metabolites.
A biomarker profile for osteoarthritis is likely to consist of multiple molecules detected in multiple tissues of the effected joint, rather than one specific molecule.
Current studies on biomarkers for osteoarthritis are built on small sample size, a variety of protocols and databases.
Clinical implementation can only be accomplished when studies have been conducted on large patient cohorts, with standardized methods and shared data.
List of abbreviations
1H NMR1H; nuclear magnetic resonance spectroscopy
2DE2D; gel electrophoresis
ACL;anterior cruciate ligament
APC;Iatmospheric pressure chemical ionization
APPI;atmospheric pressure photoionization
CI;chemical ionization
COMP;cartilage oligomeric matrix protein
DESI;desorption electrospray ionization
DMOAD;disease modifying osteoarthritis drug
ECM;extracellular matrix
EI;electron ionization
eOA;early osteoarthritis
ESI;electrospray ionization
FDR;false discovery rate
GC-MS;gas chromatography mass spectrometry
HFPH;offa’s fat pad
HPLC-MS;high performance liquid chromatography mass spectrometry
KLK;ellgren-Lawrence
LC-MS (/MS);liquid chromatography (tandem) mass spectrometry
lOA;late osteoarthritis
MALDI;matrix-assisted laser desorption/ionization
MRI;magnetic resonance imaging
MS;mass spectrometry
MSI;mass spectrometry imaging
NSAID;non-steroidal anti-inflammatory drug
OA;osteoarthritis
OPLS-DA;orthogonal partial least squares discriminant analysis
PCA;principal component analysis
SDS-PAGE;sodium dodecyl sulfate polyacrylamide gel electrophoresis
SIMS;secondary ion mass spectrometry
TKA;total knee arthroplasty
TOF;time of flight
Acknowledgments
were modified from Servier Medical Art, licensed under a Creative Common Attribution 3.0 Generic License. http://smart.servier.com/.
Declaration of interest
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Reviewer disclosures
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.